State-based surveillance for selected hemoglobinopathies
Published Date:Jul 03 2014
Source:Genet Med. 17(2):125-130.
Pubmed Central ID:PMC4427044
Funding:CC999999/Intramural CDC HHS/United States
DD09-909/DD/NCBDD CDC HHS/United States
DD10-1017/DD/NCBDD CDC HHS/United States
The lack of an ongoing surveillance system for hemoglobinopathies in the United States impedes the ability of public health organizations to identify individuals with these conditions, monitor their health-care utilization and clinical outcomes, and understand the effect these conditions have on the health-care system. This article describes the results of a pilot program that supported the development of the infrastructure and data collection methods for a state-based surveillance system for selected hemoglobinopathies.
The system was designed to identify and gather information on all people living with a hemoglobinopathy diagnosis (sickle cell diseases or thalassemias) in the participating states during 2004–2008. Novel, three-level case definitions were developed, and multiple data sets were used to collect information.
In total, 31,144 individuals who had a hemoglobinopathy diagnosis during the study period were identified in California; 39,633 in Florida; 20,815 in Georgia; 12,680 in Michigan; 34,853 in New York, and 8,696 in North Carolina.
This approach provides a possible model for the development of state-based hemoglobinopathy surveillance systems.
You May Also Like: